TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats

References

• Savage DB Petersen KF Shulman GI Disordered lipid metabolism and the pathogenesis of insulin resistance Physiol Rev 2007 87 2 507 520 17429039
   PubMed Web of Science ®Google Scholar
• Bianchi C Penno G Pancani F Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes Diabetes Res Clin Prac 2007 78 2 246 253
   PubMed Web of Science ®Google Scholar
• Despres JP Lemieux I Bergeron J Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk Arterioscler Thromb Vasc Biol 2008 28 6 1039 1049 18356555
   PubMed Web of Science ®Google Scholar
• Bugianesi E Zannoni C Vanni E Marzocchi R Marchesini G Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship? Dig Liver Dis 2004 36 3 165 173 15046183
   PubMedGoogle Scholar
• Duvnjak M Lerotic I Barsic N Tomasic V Virovic Jukic L Velagic V Pathogenesis and management issues for non-alcoholic fatty liver disease World J Gastroenterol 2007 13 4 4539 4550 17729403
   PubMed Web of Science ®Google Scholar
• Enas AE Mohan V Mohan D Syed F Pazhoor S Chennikkara H The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease J Cardiometab Syndr 2007 2 4 267 275 18059210
   PubMedGoogle Scholar
• Aristizabal D Gallo J Fernandez R Restrepo MA Zapata N Correa M The insulin gradient phenomenon: a manifestation of the effects of body weight on blood pressure and insulin resistance J Cardiometab Syndr 2008 3 4 218 223 19040590
   PubMedGoogle Scholar
• Fujita T Insulin resistance and salt-sensitive hypertension in metabolic syndrome Nephrol Dial Transplant 2007 22 11 3102 3107 17602196
   PubMed Web of Science ®Google Scholar
• Franco OH Massaro JM Civil J Cobain MR O’Malley B D’Agostino RBSr Trajectories of entering the metabolic syndrome: the framingham heart study Circulation 2009 120 20 1943 1950 19884471
   PubMed Web of Science ®Google Scholar
• Hillier TA Rousseau A Lange C Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis: the D.E.S.I.R. Cohort Diabetologia 2006 49 1528 1535 16752171
   PubMed Web of Science ®Google Scholar
• Despres JP Targeting abdominal obesity and the metabolic syndrome to manage cardiovascular disease risk Heart 2009 95 3 1118 1124 19525261
   PubMed Web of Science ®Google Scholar
• Arbeeny CM Addressing the unmet medical need for safe and effective weight loss therapies Obes Res 2004 12 8 1191 1196 15340099
   PubMedGoogle Scholar
• LaRosa JC Grundy SM Waters DD Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 2005 352 14 1425 1435 15755765
   PubMed Web of Science ®Google Scholar
• Ferreira SR Revisiting clinical trials on glycemic control and cardiovascular risk Diabetol Metab Syndr 2009 1 1 12 19825201
   PubMed Web of Science ®Google Scholar
• Fruchart JC Sacks FM Hermans MP The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diab Vasc Dis Res 2008 5 4 319 325 18958843
   PubMed Web of Science ®Google Scholar
• Cioffi F Zambad SP Chhipa L TRC150094, a novel functional analogue of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet FASEB J 2010 24 9 3451 3461 20453112
   PubMed Web of Science ®Google Scholar
• Dominguez J Wu P Packer CS Temm C Kelly KJ Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy Am J Physiol Renal Physiol 2007 293 3 F670 F679 17596532
   PubMed Web of Science ®Google Scholar
• NIH Guide for the care and use of laboratory animals NIH Publication No. 85–23. Revised 1985.
   Google Scholar
• CPCSEA CPCSEA guidelines for laboratory animal facility: committee for the purpose of control and supervision on experiments on animals Ind J Pharmacol 2003 35 257 274
   Google Scholar
• Tofovic SP Kusaka H Kost CKJr Bastacky S Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats Ren Fail 2000 22 4 387 406 10901178
   PubMed Web of Science ®Google Scholar
• Lanni A Moreno M Cioffi M Goglia F Effect of 3,3′-diiodothyronine and 3,5-diiodothyronine on rat liver oxidative capacity Mol Cell Endocrinol 1992 86 3 143 148 1324858
   PubMed Web of Science ®Google Scholar
• Luna LG Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology 3rd ed New York McGraw-Hill Book Company 1968
   Google Scholar
• Joshi D Gupta R Dubey A TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes J Cardiovasc Pharmacol 2009 54 1 72 81 19546815
   PubMed Web of Science ®Google Scholar
• Nisoli E Clementi E Carruba MO Moncada S Defective mitochondrial biogenesis: a hallmark of the high cardiovascular risk in the metabolic syndrome? Circ Res 2007 100 6 795 806 17395885
   PubMed Web of Science ®Google Scholar
• Zidek W Naditch-Brule L Perlini S Farsang C Kjeldsen SE Blood pressure control and components of the metabolic syndrome: the GOOD survey Cardiovasc Diabetol 2009 8 51 19754934
   PubMed Web of Science ®Google Scholar
• Regensteiner JG Bauer TA Reusch JE Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus J Appl Physiol 1998 85 1 310 317 9655791
   PubMed Web of Science ®Google Scholar